Sagimet Biosciences reported total assets of $263.43M and total liabilities of $7.28M for the quarter ended Jun 2026, up 91.7% year over year. This balance sheet covers 17 quarters of results from Jun 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||
| Current Assets | |||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 0.20M | 18.51M | 101.84M | 75.14M | 176.78M | 95.96M | 77.01M | 75.84M | 64.72M | 42.33M | 32.50M | 35.02M | 36.63M | 165.90M | |||
| Prepaid Assets | 0.45M | 2.85M | 0.97M | 1.75M | 0.79M | 0.38M | 4.70M | 1.52M | 1.50M | 1.79M | 2.79M | 3.28M | 3.18M | 3.86M | |||
| Current Assets | 32.79M | 21.35M | 102.82M | 96.65M | 194.49M | 166.75M | 157.19M | 152.77M | 146.07M | 127.20M | 119.48M | 116.40M | 107.72M | 243.99M | |||
| Non-Current Assets | |||||||||||||||||
| Long-Term Investments | 22.12M | 17.47M | 7.41M | 10.06M | 8.81M | 17.44M | |||||||||||
| Other Non-Current Assets | 0.03M | 0.06M | 0.06M | ||||||||||||||
| Non-Current Assets | 0.24M | 0.14M | 0.11M | 0.07M | 0.04M | 22.27M | 17.59M | 7.49M | 0.10M | 10.21M | 8.92M | 0.08M | 0.04M | 19.44M | |||
| Assets | 33.03M | 21.50M | 102.92M | 96.72M | 194.53M | 189.02M | 174.78M | 160.26M | 146.17M | 137.41M | 128.40M | 116.48M | 107.75M | 263.43M | |||
| Liabilities | |||||||||||||||||
| Current Liabilities | |||||||||||||||||
| Accounts Payables | 1.12M | 2.72M | 1.70M | 0.19M | 0.53M | 1.99M | 1.15M | 1.43M | 3.22M | 1.92M | 4.24M | 1.31M | 2.30M | 1.13M | |||
| Payables | 1.12M | 2.72M | 1.70M | 0.19M | 0.53M | 1.99M | 1.15M | 1.43M | 3.22M | 1.92M | 4.24M | 1.31M | 2.30M | 1.13M | |||
| Accumulated Expenses | 4.02M | 2.42M | 3.24M | 5.40M | 3.95M | 3.58M | 2.82M | 2.95M | 3.92M | 5.17M | 4.79M | 3.71M | 2.96M | 4.20M | |||
| Other Accumulated Expenses | 0.06M | 0.10M | 0.10M | 0.23M | 0.01M | 0.01M | 0.01M | 0.02M | 0.00M | 0.01M | 0.03M | 0.01M | 0.03M | ||||
| Current Leases | 0.13M | 0.14M | 0.10M | 0.07M | 0.03M | 0.15M | 0.12M | 0.08M | 0.04M | 0.15M | 0.12M | 0.08M | 0.04M | 0.08M | |||
| Total Current Liabilities | 5.28M | 5.29M | 5.05M | 5.65M | 4.45M | 7.25M | 9.15M | 5.10M | 5.30M | 5.42M | |||||||
| Non-Current Liabilities | |||||||||||||||||
| Preferred Stock Liabilities | 214.62M | 214.62M | 214.62M | 214.62M | 214.62M | ||||||||||||
| Operating Leases | 0.08M | 1.86M | |||||||||||||||
| Other Non-Current Liabilities | 0.00M | 0.01M | 0.00M | ||||||||||||||
| Total Non-Current Liabilities | 5.36M | 5.29M | 5.05M | ||||||||||||||
| Total Liabilities | 173.42M | 180.55M | 5.36M | 192.70M | 5.29M | 5.05M | 5.65M | 4.51M | 5.73M | 4.09M | 4.45M | 7.18M | 7.25M | 9.15M | 5.10M | 5.30M | 7.28M |
| Shareholder's Equity | |||||||||||||||||
| Common Equity | -173.42M | -180.55M | -186.95M | -192.70M | -198.41M | 97.88M | 91.06M | 190.02M | 183.29M | 170.68M | 155.81M | 138.99M | 130.16M | 119.25M | 111.38M | 102.46M | 256.15M |
| Liabilities and Shareholders Equity | 33.03M | 21.50M | 102.92M | 96.72M | 194.53M | 189.02M | 174.78M | 160.26M | 146.17M | 137.41M | 128.40M | 116.48M | 107.75M | 263.43M | |||
| Retained Earnings | -221.87M | -235.24M | 339.47M | 340.78M | 446.38M | 447.80M | 449.35M | 450.88M | 452.36M | 453.95M | 455.92M | 457.61M | 459.45M | 627.18M | |||
| Treasury Shares | 1,373.73M | 1,373.73M | 1,373.73M | 1,373.73M | 1,373.73M |